Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5815924 | 0.85 | NPC1 (0.45) | NAAAEPHX1NPC1RAB9AALDH1A1 | |
| SCHEMBL2085864 | 0.85 | LPL (0.47) | NAAAEPHX1NPC1RAB9AALDH1A1 | |
| SCHEMBL2083250 | 0.84 | CYP1A2 (0.49) | NAAAEPHX1 | |
| SCHEMBL4141687 | 0.83 | HDAC11 (0.45) | NAAAEPHX1NPC1RAB9AALDH1A1 | |
| SCHEMBL4137357 | 0.83 | NAAA (0.58) | NAAAEPHX1NPC1RAB9AALDH1A1 | |
| SCHEMBL3210607 | 0.83 | NAAA (0.49) | NAAAEPHX1NPC1RAB9AALDH1A1 | |
| SCHEMBL2086284 | 0.83 | LPL (0.46) | NAAAEPHX1NPC1RAB9AALDH1A1 | |
| SCHEMBL2085239 | 0.83 | CYP1A2 (0.48) | NAAANPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL4144101 | 0.80 | LTB4R2 (0.52) | NPC1RAB9AALDH1A1HTTLTB4R2 | |
| SCHEMBL4140925 | 0.79 | CNR1 (0.43) | NAAAEPHX2HTTTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| WO-2009077844-A2 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | QUONOVA LLC (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | PGLS, TFPI, Q6ZSR9 | NAAA 213/4885EPHX1 4403/4885NPC1 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.